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Add-on treatment with pyridoxine and sulthiame in 12
infants with West syndrome: an open clinical study
OTFRIED MARTIN DEBUS†, JESSIKA K ¨OHRING, BARBARA FIEDLER, MAIKE FRANSSEN &
GERHARD KURLEMANN
University Children’s Hospital, Department of Neuropediatrics, Westfa¨lische-Wilhelms-Universita¨t
Mu¨nster, Albert-Schweitzer-Str. 33, D - 48149 Mu¨nster, Germany
To investigate the effect of sulthiame (STM) in West syndrome (WS) an open, uncontrolled add-on study was undertaken during
initial pyridoxine (PDX) therapy in 12 infants, two with idiopathic and ten with symptomatic WS. All patients were initially
treated with PDX (150–300 mg kg−1 body weight day−1). In seven patients (58%) seizures and hypsarrhythmia stopped during
the week after introduction of STM (10 mg kg−1 body weight day−1). In one the positive effect was temporary. Five of the
responders (42%) remained seizure-free and without hypsarrhythmia under STM monotherapy, while one developed complex
partial seizures after 25 months. STM was most effective in idiopathic WS (2/2). During treatment with STM medication no
patient suffered side effects attributable to the substance. Further controlled studies are necessary to evaluate the benefit of this
potentially effective treatment.
c© 2002 Published by Elsevier Science Ltd on behalf of BEA Trading Ltd.
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INTRODUCTION
As the basic mechanisms of epileptogenesis in West
syndrome (WS) are still unclear, treatment is mainly
empirically based, and an internationally accepted
gold standard is lacking. Since the first report on
the efficacy of ACTH in 19501 many controlled
studies with ACTH or steroids have confirmed the
still unrivalled benefit of this therapy, recording initial
responder rates of up to 90% for ACTH2. However,
high relapse rates of 35 to 50%3 and a substantially
elevated therapy associated morbidity and mortality
curtail the initial therapeutic benefit4.
Valproic acid is reported to control spasms in 65%
of cases within three months5. Similar effects in 48–
60% of cases were reported for topiramate6 or vigaba-
trin7, 8. Following reports on a beneficial effect of high
doses of pyridoxal phosphate in up to 40% of crypto-
genic and 10% of symptomatic WS cases9, 10 an initial
1–2 week course of pyridoxine (PDX) has become
established in some European countries and Japan.
Until now the sulphonamide derivative and carboan-
hydrase inhibitor sulthiame (STM), which is used to
treat benign partial epilepsies, has not been trialed in
WS.
To test whether the hypothesis of STM being
effective in WS might justify a controlled study, we
added STM openly to our standard initial PDX therapy
in children with newly diagnosed WS.
METHODS
Twelve boys aged 4–12 months with newly diagnosed
WS (two idiopathic, ten symptomatic, Table 1) were
enrolled in the study with informed parental consent.
Five of those with symptomatic WS had chromosomal
abnormalities, two had been born prematurely, one
had fetal alcohol syndrome, one showed cerebral
dysgenesis, and one had porencephaly.
One infant suffering from Down syndrome, poren-
cephaly and focal seizures (no. 9, Table 1) developed
WS whilst undertaking antiepileptic therapy with phe-
nobarbitone; which was stopped at the commencement
of PDX therapy. None of the others had received
antiepileptic drugs (AEDs) before developing WS.
All patients received orally administered baseline
PDX therapy (300 mg kg−1 body weight day−1 div-
ided into six doses). This was reduced to 150 mg kg−1
body weight day−1 or administered intravenously
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Table 1: Anamnestic and therapeutic data of 12 patients with West syndrome.
Patient Sex Previous history Onset of West Successful Ineffective Follow-up Course with
MRI scan syndrome treatment substances (months) ref. to
(months) seizures
1 m Focal neonatal seizures, 4 STM, PDX PB, VGB 35 Seizure free
left hemispheric dysgenesis LTG for 24 mo,
then CPSc
2 m Thrombasthenia Glanzmann, 9 STM PDX 28 Seizure free
fetal alcohol syndrome, for 28 mo
micro-cephaly, global brain atrophy
3 m Recurrent pneumo-thorax, 8 STM PDX 29 Seizure free
MRI normal for 29 mo
4 m Down syndrome, 12 DEX STM 23 Seizure free
AV septal defect, for 21 mo
mitral valve replacement
5 m 46, XY, +inv dup (15) 9 (STM, PDX)b CLB 21 CPS and
no abnormalities in MRI VGB focal motor
seizures
6 m Preterm 32 weeks GA, 8 (6)a VPA PDX, STM, 24 Rare grand
esophageal atresia, VGB, CLB, PB mal seizures
46, XY, transl/del. (5p–1p)
7 m Preterm 27 weeks GA, 10 (7)a VGB PDX, STM, 20 CPS
IVH I-II, hydrocephalus, PB
right occipital defect
8 m Down syndrome 16 ACTH, LTG PDX, STM, 19 Seizure free
CLB,VGB for 17 mo
9 m Down syndrome, 5 PDX, STM, PB, 22 Secondary
right porencephaly VGB, ACTH, generalized
VPA seizures
10 m No abnormality 4 STM VGB, VPA 18 Seizure free
for 18 mo
11 m Left porencephaly, 8 STM PDX 9 Seizure free
right temporal atrophy for 9 mo
12 m Preterm 30 weeks GA, 9 (7)a STM PDX 6 Seizure free
IVH II-III, enlarged ventricular for 6 mo
spaces, cerebral atrophy
a conception adjusted age; b temporarily effective; c CPS = complex partial seizures; GA = gestational age; IVH = intraventricular
hemorrhage; STM = sulthiame; PDX = pyridoxine; LTG = lamotrigine; DEX = dexamethasone; VGB = vigabatrin; VPA = valproate;
ACTH = adrenocorticotrophic hormone; PB = phenobarbitone; CLB = clobazame.
if gastrointestinal side effects interfered with PDX
absorption. After three to four days of PDX alone,
STM was added in a dose of 5 mg kg−1 body
weight day−1. If this had no significant effect on
spasms or hypsarrhythmia, the dose was increased
to 10 mg kg−1 body weight day−1. Patients were
reviewed before the introduction of STM, on the day
of dose escalation, and three days after high dose
treatment with STM. EEG monitoring (including a
period of sleep) was performed at each of these
stages. Patients were classified as responders if
infantile spasms had stopped and the EEG showed no
hypsarrhythmia; however, the EEG tracing could still
contain focal or multifocal epileptic discharges.
RESULTS
None of the patients responded to the initial phase of
PDX monotherapy.
Six patients showed a permanent response, with
two (nos. 3 and 12, Table 1) becoming seizure-free
after the introduction of low doses of STM, but with
hypsarrhythmia ceasing only with an increased STM
dosage. In the other four patients (nos. 2, 10, 11
and 12, Table 1) both spasms and hypsarrhythmia
ceased during the high-dose STM phase. In one briefly
responding patient (no. 5, Table 1), the effect did not
outlast the increase of STM dosage.
The STM responders included the two children with
idiopathic WS but none of the symptomatic patients
with chromosomal abnormalities.
In all the responding infants the PDX medication
was phased out over a period of 4–6 weeks;
neither infantile spasms nor hypsarrhythmia recurred
thereafter.
The follow up period lasted from 6 to 35 months in
the responding patients. One patient (no. 1) remained
seizure-free for 25 months before developing complex
partial seizures which responded to phenytoin. The
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other five patients successfully treated with STM had
no relapse to WS nor did they develop other kinds of
seizures. Two of them (nos. 2 and 3) are medication-
free after 28 and 29 months respectively.
DISCUSSION
Although its major antiepileptic mechanisms are un-
clear, the sulphonamide derivative and carboanhydrase
inhibitor, STM, may act by lowering the extracellular
concentration of K⊕ and pH, leading to a decrease of
neuronal excitability11. Its anticonvulsant properties
are used mainly in the treatment of benign partial
epilepsies, as reported in a recent double blind placebo
controlled multicenter study12. Until now, however,
this drug has not been used in the treatment of WS. In
view of the good tolerability of STM13 and its quick
onset of action, this open pilot study was initiated
for patients with newly diagnosed WS who, with one
exception, had received no previous AED.
50% of the treated patients (6/12) exhibited a pos-
itive response regarding spasms and hypsarrhythmia
throughout the follow up period of up to 35 months. A
possible synergistic effect of STM and PDX cannot be
proven with this approach but appears unlikely in view
of the lasting effect in the responders despite the early
withdrawal of PDX. As reported for ACTH and other
AEDs in previous studies14, patients with idiopathic
WS responded best (2/2). Infants with chromosomal
abnormalities had no benefit from this medication,
reflecting the poorer prognosis in symptomatic WS.
Neither the design of the study nor the numbers of
patients enrolled allow statistical conclusions to be
drawn about the effect of STM. Comparison of the
results of this observation with historical data of initial
PDX monotherapy suggests that the antiepileptic
properties of STM in WS may exceed those of PDX.
Further controlled studies are needed to confirm this
hypothesis.
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